Latest news with #Gut
Bangkok Post
15 hours ago
- Business
- Bangkok Post
PRÉCIEUX Debuts with Five Independent Watch Brands
PRÉCIEUX, the independent Swiss watch retailer, made its official Thailand debut at the end of July 2025 with a high-profile launch at Riedel Wine Bar & Cellar, Gaysorn Village. Founder of PRÉCIEUX (SWISS) and CEO of PRÉCIEUX (Thailand) Mr Marcel Gut, together with Mr Ravis Haetanurak, Chief Operating Officer of PRÉCIEUX (Thailand), welcomed distinguished guests and members of the media. The event drew significant interest from watch collectors and industry press. The evening was moderated by Dr Pramote Rienjaroensuk, with Mr Gut delivering the opening speech alongside Mr Ravis, before joining a discussion on the event's objectives. The establishment of PRÉCIEUX (Thailand) stems from the vision of Mr Marcel Gut and Mr Ravis Haetanurak, both of whom have long been active in the Swiss watch industry and in Thailand. Mr Gut, founder of PRÉCIEUX (SWISS), represents independent watch brands in multiple countries and has observed a growing global trend among collectors seeking greater diversity and excitement from emerging marques. Increasingly, enthusiasts are looking beyond familiar names to discover exceptional, independent, high-quality watch brands. Some of these brands boast rich histories, distinctive identities and craftsmanship handed down through generations of watchmaking families. This launch offers Thai collectors the opportunity to own timepieces that are unique in both design and heritage. In line with this vision, Mr Gut has chosen Thailand as the location for the brand's first PRÉCIEUX Watch Lounge, opening later this year on the lobby level of President Tower Arcade at InterContinental Bangkok. Designed as 'A Curated House of Independent Watchmaking', the lounge will showcase the finest independent watchmakers, celebrated for their creative freedom and uncompromising quality.
Time of India
5 days ago
- Health
- Time of India
Irritable bowel syndrome with diarrhea: How INSL5 hormone targeting offers new treatment hope
Irritable Bowel Syndrome with diarrhea (Irritable bowel syndrome with diarrhea) is a prevalent digestive disorder affecting millions of people worldwide. Those living with Irritable bowel syndrome with diarrhea often experience frequent, sometimes unpredictable diarrhea, along with abdominal pain, cramping, bloating, and an urgent need to use the restroom. These symptoms can significantly disrupt daily routines, social activities, and mental well-being, making even simple tasks challenging. Conventional treatments for Irritable bowel syndrome with diarrhea typically focus on managing symptoms rather than addressing the underlying cause, leaving many patients frustrated and searching for more effective solutions. However, recent research from the University of Cambridge has shed new light on a gut hormone called Insulin-Like Peptide 5 (INSL5), identifying it as a major contributor in up to 40% of Irritable bowel syndrome with diarrhea cases. This discovery, published in the journal Gut , highlights a clear biological mechanism behind the disorder, paving the way for targeted therapies and more accurate diagnosis. Understanding the role of INSL5 could transform the way Irritable bowel syndrome with diarrhea is treated, offering hope for improved symptom control and a better quality of life for those affected. By focusing on the hormone's influence on gut function, researchers aim to develop therapies that go beyond temporary relief, addressing the root causes of Irritable bowel syndrome with diarrhea and empowering patients to regain control over their digestive health. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Ukraine: Unsold Sofas at Bargain Prices (Prices May Surprise You) Sofas | Search Ads Search Now Undo What is INSL5 and its connection to Irritable bowel syndrome with diarrhea INSL5 is a hormone secreted in the gut that plays a key role in regulating bowel movements. Research has shown that elevated levels of INSL5 are associated with chronic diarrhea, offering a potential explanation for a significant portion of Irritable bowel syndrome with diarrhea cases, especially in patients with bile acid malabsorption. By influencing intestinal motility and fluid secretion, INSL5 contributes directly to the frequent, urgent diarrhea and discomfort experienced by those with Irritable bowel syndrome with diarrhea. Targeting INSL5 presents an opportunity for more precise and effective treatment, focusing on the underlying cause rather than merely managing symptoms. This approach could lead to therapies that improve quality of life, reduce dependency on broad-acting medications, and provide long-term relief for patients who have struggled with conventional symptom-based treatments. Understanding the hormone's role also opens the door to more accurate diagnostics, enabling healthcare providers to identify those most likely to benefit from targeted interventions. How targeting INSL5 could improve diagnosis and treatment Measuring INSL5 levels in patients offers a promising method to differentiate Irritable bowel syndrome with diarrhea from other gastrointestinal conditions, which often present with similar symptoms such as diarrhea, bloating, and abdominal discomfort. Accurate identification can lead to earlier and more targeted interventions, helping patients avoid unnecessary treatments and prolonged symptom management. Existing medications that influence gut hormones, like ondansetron, have already shown some success in relieving diarrhea and improving quality of life, suggesting that hormonal pathways can be effectively modulated. Building on this knowledge, therapies designed specifically to target INSL5 could provide a more precise approach, addressing the underlying cause of Irritable bowel syndrome with diarrhea rather than just mitigating symptoms. Such targeted treatments could transform patient care by reducing flare-ups, enhancing day-to-day comfort, and offering a more personalized strategy for managing this challenging digestive disorder. Research and future directions of INSL5 for Irritable bowel syndrome with diarrhea Ongoing studies are exploring the development of INSL5-inhibiting drugs as well as diagnostic tests that could enable truly personalized management of Irritable bowel syndrome with diarrhea. By gaining a deeper understanding of how this hormone regulates bowel movements, researchers hope to reduce misdiagnoses and limit the need for trial-and-error treatments, which are often frustrating and time-consuming for patients. Targeted therapies focusing on INSL5 could provide faster, more reliable relief, directly addressing the root cause of diarrhea and other symptoms. Over time, this approach has the potential to revolutionize Irritable bowel syndrome with diarrhea care, offering patients a more precise, effective, and sustainable solution that improves daily quality of life and long-term digestive health. Targeting INSL5 has the potential to revolutionize Irritable bowel syndrome with diarrhea management by offering precision treatment for the subset of patients who have long struggled with chronic diarrhea. This breakthrough underscores the critical role gut hormones play in regulating digestive health and opens the door to therapies that address the underlying cause rather than just masking symptoms. By focusing on INSL5, researchers aim to provide more effective, personalized solutions that improve symptom control, enhance quality of life, and reduce the trial-and-error approach often associated with conventional Irritable bowel syndrome with diarrhea treatments. This discovery marks a significant step forward in understanding and managing this challenging condition. Also read| Why every Indian should add vitamin D, B12, and Omega-3 to their diet "Get the latest news updates on Times of India, including reviews of the movie Coolie and War 2 ."
Business Wire
06-08-2025
- Business
- Business Wire
Former FDA Director and Boston Scientific Leaders Join Keyron Ahead of Human Trials of First Device with Metabolic Surgery-Like Results Without Incisions
LONDON & BOSTON--(BUSINESS WIRE)-- Keyron, a pioneer in medical devices for advanced metabolic disease, today announced the appointment of three world-class leaders to its board of directors—including the former Director of the FDA's Center for Devices and Radiological Health (CDRH) and senior medtech industry leaders with key roles in notable exits within the endoscopy medical device sector. These appointments strengthen Keyron's regulatory, clinical, and strategic leadership as the company prepares for its upcoming clinical trials, associated global regulatory submissions, and future strategic alliances, centered around its ForePass device. ForePass is designed to replicate the outcomes of metabolic surgery—without cutting, puncturing, or trauma—through a fully reversible, minimally invasive procedure. Board Appointments David Feigal MD (Head of Regulatory Affairs) – Former Director of the FDA's Center for Devices and Radiological Health (CDRH). Covered the highest role and authority in medical devices at the FDA. Brings decades of experience guiding breakthrough technologies through FDA approval and will now be the Company's lead for FDA engagement and IDE submission. Founder of leading U.S. regulatory consultancy, NDA Partners. Widely recognized as one of the most experienced regulatory experts in the U.S., he has held senior global roles at public companies Amgen and Elan and led or advised over 20 successful medical product approvals across therapeutic areas. Joyce Peetermans, Ph.D. (Acting CTO) – 35+ years of leadership roles in R&D, Clinical Research, and Innovation in Gastroenterological and Surgical Endoscopy, and other specialties. She spent 25 years at Boston Scientific, where she was on the Endoscopy Management Board as VP of Global Clinical Programs, and VP of Innovation and Research during the $615M acquisition of Apollo Endosurgery and several other key acquisitions by Boston Scientific Endoscopy. Christopher Rowland (Chairman) – A seasoned executive with over 35 years leading Class III endoscopic and metabolic device companies. He served as President at Given Imaging prior to its $860M PillCam exit to Covidien (Medtronic) and was CEO of Neotract before its $1.1B acquisition by Teleflex. He also spent 17 years in senior roles at Boston Scientific. Christopher will chair Keyron's board of directors and support its corporate development and fundraising strategy. This leadership expansion follows several successful large-animal studies of ForePass demonstrating excellent safety, tolerability, and strong efficacy on both weight and insulin production. Key results were published in Gut (Angelini G, Galvao Neto M, Boskoski I, et al., 2024), showing ForePass's ability to replicate surgery-like results without incisions. The company is now preparing to unveil best-in-class preclinical data showing clear superiority over Semaglutide—the $28B/year standard of care for obesity and diabetes in Ozempic and Wegovy—across all major endpoints. These data are expected to be published this summer. 92% of Semaglutide patients fail to achieve 15% total body weight loss (New England Journal of Medicine, 2021; 385(6):503–515), with 85% discontinuing GLP-1 therapy within just 24 months (Reuters, 10 July 2024). Yet patients with severe obesity (BMI ≥35)—especially those who also have type 2 diabetes—need around 30% weight loss. Since GLP-1s fall substantially short and most stop taking them, surgery remains the only viable option, regularly delivering over 30% weight loss despite its risks and complications. ForePass is a fully removable, endoscopically implantable device aiming to replicate the metabolic benefits of surgery without incisions. It targets patients with BMI ≥35 and diabetes or BMI ≥40—a large, high-risk population underserved by current treatments. Giorgio Castagneto Gissey, Founder & CEO of Keyron, said: 'Christopher, David, and Joyce are absolute world-class leaders. Their decision to join Keyron reflects the urgency of the metabolic crisis—especially the unmet need in diabetes and higher BMI—and the unique power of what we've built. Their expertise will be transformative as we enter human trials and deliver the first truly effective, scalable alternative to surgery for millions.' Keyron, a VC-backed startup, has developed a proprietary biometabolic implant and endoscopic delivery system, secured leading clinical sites in the U.S. and internationally, and completed long-term preclinical validation. Full efficacy results—including head-to-head data versus Semaglutide in a porcine model—will be published shortly. The company is now preparing for its First-In-Human study. About Keyron Keyron is the first biometabolic device platform company, pioneering a new class of implantable therapies that aim to replicate the effects of bariatric and metabolic surgery without incisions—and restore metabolic health at its root without driving insulin overproduction or dependency. Headquartered in London and Boston, Keyron's mission is to deliver a scalable alternative to surgery—and a better option for patients with severe obesity and diabetes. See for more information.
New York Post
23-06-2025
- Health
- New York Post
5 health issues that can worsen in a heat wave — including how high temps can trigger a heart attack and stroke
This week, millions of Americans — including New Yorkers — are grappling with what forecasters are calling a 'very sweaty' heatwave. It's miserable — but it's worth remembering that, without the proper precautions, it's also extremely dangerous. Dehydration can cause dizziness, headaches, low blood pressure, blurred vision, kidney problems and, in extreme cases, fatal heatstroke. Advertisement And that's just in healthy people. 3 Dr. Thomas Gut and Dr. Nima Majlesi explain how high temperatures can increase the risk of heart attack and stroke, kidney issues, respiratory problems and more. realstock1 – While everyone should try to stay cool and hydrated in these sizzling temperatures, The Post spoke to two doctors who warn that people with these health issues are at especially high risk. Heart disease 'Those with cardiovascular disease are at high risk since these patients are often asked to limit fluid intake,' Dr. Thomas Gut, Associate Chair of Medicine at Northwell's Staten Island University Hospital, told The Post. Advertisement 'Sweating beyond the normal daily expected amount can lead to significant fluid shifts and electrolyte imbalances that can cause significant harm, especially to those already taking diuretics medications.' Dr. Nima Majlesi, who practices emergency medicine at the same hospital, told The Post that high temperatures can mess with the normal blood flow to the heart, potentially causing acute coronary syndrome, which spikes the risk of heart attack. When you get really hot, your body needs to work harder to cool you down, which can also place more strain on the heart. Advertisement For this reason, people who are at risk for heart failure are also in danger of getting worse in the heat, Majlesi noted. 3 Gut warns that people with respiratory diseases are at greater risk because 'hot air, especially if humid, can trigger patients with even well-controlled breathing conditions into rapid and shallow breathing.' cunaplus – Respiratory diseases It's normal to experience some difficulty breathing when it's really hot, because your body's attempts to cool down require more oxygen. Advertisement However, Gut warns that people with respiratory diseases are at greater risk because 'hot air, especially if humid, can trigger patients with even well-controlled breathing conditions into rapid and shallow breathing.' Those who depend on supplied oxygen are of particular concern, since power outages are more common during heatwaves due to 'the increased demand for homes needing cooling — power outages can leave those vulnerable patients without additional oxygen supplies,' he said. 3 Drink half a glass of water per hour, or as instructed by your own doctor, to stay properly hydrated. Antonioguillem – Kidney disease 'Patients with kidney disease are also at high risk for electrolyte imbalances as their hydration status and sweating fluctuates during heatwaves,' Gut said. Psychiatric conditions and drug users 'In younger populations, neuropsychiatric conditions and underlying drug use disorders create a very high risk for issues with heat stroke,' Majlesi said. 'Cocaine-related deaths increase exponentially during heat waves, for example.' Cocaine is a stimulant that increases your body temperature and puts extra strain on your heart, both of which can cause serious issues during a heatwave. Advertisement The same goes for other psychological conditions that put your heart to work — such as anxiety. Anyone on medication that slows down the body's natural cooling process 'Diuretics, allergy medications and psychiatric medications can all create issues in this patient population,' Majlesi said. To stay safe, Gut recommends the following:
The Independent
31-01-2025
- Health
- The Independent
Eight ways to reduce your risk of bowel cancer
A new study offers hope for more accurate bowel cancer risk prediction in people with inflammatory bowel disease (IBD). The research, funded by Cancer Research UK and published in the journal Gut, demonstrates over 90 per cent accuracy in predicting bowel cancer risk within five years for a high-risk IBD group. Individuals with conditions like Crohn's disease and ulcerative colitis face a heightened risk of bowel cancer. Current routine screenings detect pre-cancerous growths, indicating a 30 per cent chance of developing bowel cancer within a decade. However, this new study reveals a more precise method. By analysing DNA alterations in pre-cancerous cells using a specialised algorithm, researchers achieved significantly improved predictive accuracy. This breakthrough raises the possibility of a simple blood test to identify high-risk IBD patients, potentially revolutionising early detection and intervention strategies. 'For people without a condition like Crohn's or colitis, there are many lifestyle changes that can help reduce the risk of bowel cancer.' So, here are 8 ways to reduce your risk of bowel cancer. 1. Stop smoking 'Seven out of 100 bowel cancers in the UK are linked to smoking and the risk increases with the number of cigarettes smoked a day, so stopping smoking is an important way to reduce your risk,' advises Sturt. 2. Reduce intake of red meat 'Diet plays an important role in the development of the disease,' highlights Sturt. 'Reducing your intake of red and processed meat will help decrease the chance of getting bowel cancer. 'For example, you could swap out beef, sausages and bacon for chicken or fish.' 3. Feed yourself with fibre 'Fibre has many important functions within the bowel, such as increasing the weight and size of your stool and softening it, so it's easier to pass,' explains Dr Dave Nichols, NHS GP and resident doctor for at-home testing provider MyHealthChecked. 'It's crucial to aim for 30g of fibre a day, which is available from wholemeal bread, brown rice, fruit and veg, beans and oats.' 4. Increase calcium intake 'Getting plenty calcium can help decrease the chance of getting bowel cancer,' says Sturt. 'Add milk and dairy to your diet for calcium – or non-dairy alternatives that have calcium added.' 5. Avoid ultra-processed food 'Limiting the intake of ultra-processed food is also important; reduce the intake of things such as crisps, breakfast cereals, sausages, ham, and mass-produced bread,' advises Nichols. 6. Maintain a healthy weight 'Being overweight increases your risk of bowel cancer,' says Sarah Sweenie, health information and evidence manager at Bowel Cancer UK. 'To manage your weight, be mindful of portion sizes, avoid sugary drinks, limit alcohol consumption, and choose healthy snacks like fruits and vegetables.' 7. Limit alcohol consumption 'Alcohol is linked to an increased risk of developing several types of cancer including bowel cancer,' says Sweenie. 'If you do drink alcohol, cutting down the amount you drink will reduce your risk. 'It's recommended that men and women drink no more than 14 units of alcohol a week and spread it out over the week. Aim to have at least two alcohol free days a week.' 8. Stay physically active Regular physical activity can help reduce your risk. 'Aim for at least 150 minutes of activity, such as brisk walking, cycling, or swimming, each week,' recommends Sweenie. 'This not only helps maintain a healthy weight but also keeps your digestive system healthy. 'If you don't do much physical activity, try starting with 10 minutes and increase the time gradually.'
